CSL Ltd

CSL

Company Profile

  • Business description

    CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

  • Contact

    655 Elizabeth Street
    MelbourneVIC3000
    AUS

    T: +61 393891911

    E: [email protected]

    https://www.csl.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    29,904

CSL Ltd News & Analysis

investing

Podcast: Investing Compass

Morningstar Australia's podcast series.
stocks

ASX healthcare leader sees further cuts to fair value

Fiercer competition expected to squeeze margins.
stocks

Top stocks of the year: Which opportunities remain in 2026?

A deep dive into the most traded stocks by Aussies in 2025 - and what this signals for the year ahead.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,552.6077.000.91%
CAC 407,507.44158.18-2.06%
DAX 4021,890.63489.56-2.19%
Dow JONES (US)45,577.47443.96-0.96%
FTSE 1009,712.80205.53-2.07%
HKSE24,382.47894.85-3.54%
NASDAQ21,647.61443.08-2.01%
Nikkei 22551,515.491,857.04-3.48%
NZX 50 Index12,899.7290.27-0.69%
S&P 5006,506.48100.01-1.51%
S&P/ASX 2008,365.9082.400.99%
SSE Composite Index3,813.28143.77-3.63%

Market Movers